A dose-dependent inhibition of fibronectin-stimulated haptotaxis was seen with MDA-MB-231 and Hs578T cells with a reduction of 51, and 47%, respectively, at the higher dose. signaling. Of note, treatment with recombinant LOX-PP selectively reduced fibronectin-mediated haptotaxis of NF639, MDA-MB-231, and Hs578T breast cancer cells. Thus, evidence is provided that one mechanism of action of LOX-PP tumor suppression is to block fibronectin-stimulated signaling and cell migration. Thelysyl oxidase(LOX)2gene family is comprised of five membersLOX, LOXL1, LOXL2, LOXL3,andLOXL4, which encode enzymes that modify extracellular matrix (ECM) proteins to promote their cross-linking and deposition (1). TheLOXgene is the best characterized and codes for the synthesis of a secreted 50-kDa glycosylated pro-enzyme (Pro-LOX). Pro-LOX is extracellularly processed by proteolytic cleavage to a mature active 32-kDa enzyme (LOX) and an 18-kDa pro-peptide (LOX-PP) by the procollagen C Rabbit polyclonal to Smac proteinases bone morphogenic protein-1 (BMP-1), and the related tolloid-like proteins TLL1 and TLL2 (24). In murine Pro-LOX, proteolytic processing occurs between amino acids Gly-162 and Asp-163, generating LOX-PP containing 141 amino acids (5). LOX-PP contains two consensusN-glycosylation sites, Asn-91 and Asn-138 (murine sequence) (2) and severalO-glycosylation sites.3LOX-PP does not contain any known protein domains, and structural prediction analysis indicates that LOX-PP assembles as L-cysteine an intrinsically disordered protein (6). Among the LOX family members, the C-terminal ends encode the enzyme domain and are highly conserved, whereas the N-terminal ends that encode the pro-peptide region have variable sequences. Based on structural and sequence similarities of the pro-peptide regions, the LOX family members can L-cysteine be divided into two subgroups:LOXL2, LOXL3, andLOXL4as one group whose propeptide regions contain four scavenger receptor cysteine-rich domains, andLOXandLOXL1as a separate group with much simpler and smaller pro-peptide region containing no cysteine residues (reviewed in Ref.1). In contrast to Pro-LOX, the exact maturation site of Pro-LOXL1 is still unidentified. LOX is essential in the formation of blood vessels and in maintaining their normal characteristics (79). Up-regulation ofLOXexpression has been described in stromal cells that surround ductal breast and broncho-pulmonary carcinomas (10). Expression of theLOXgene was found to inhibit the transforming activity of theRasoncogene in NIH 3T3 fibroblasts and hence was named the ras recision gene (rrg) (11,12). TheLOXgene was shown to inhibit growth in soft agar of NIH 3T3 fibroblasts and to attenuate Ras-mediated activation of phosphatidylinositol 3-kinase (PI3K), Akt, and Erk1/2 kinases and NF-B activation (13). More recently, therrgactivity was mapped to the 18-kDa LOX-PP. Specifically, LOX-PP was shown to inhibit Ras-mediated transformation of fibroblasts as determined by reduced growth in soft agar, localization of PDK1 to the membrane, and activation of NF-B (14). Furthermore, the inhibitory effects L-cysteine of LOX-PP on Ras signaling were extended to breast, pancreatic, and lung cancer cells (6,14,15). LOX-PP expression in these carcinoma cells reverted Her-2/neu- and Ras-mediated epithelial to mesenchymal transition (EMT), leading to increased expression of E-cadherin and -catenin, and reduced levels of Snail, vimentin, and/or BCL-2 (7,15). Furthermore, LOX-PP expression reduced tumor formation in a xenograft model by Her-2/neu-overexpressing NF639 cells (6). Acquisition of the ability to invade the ECM is essential to EMT. The ECM has multiple mechanical and signaling functions. The ECM defines interfaces between tissues, provides a L-cysteine scaffold for cell traction, and a substrate for cell migration and adhesion. It is composed of a complex of proteins such as collagens, fibronectin, and laminin, which can interact and bind various growth factors (16). Fibronectin is definitely of particular interest because it was recently shown to interact with the C terminus of Pro-LOX (17). Binding of fibronectin to its receptors (e.g.integrins 51or v1) stimulates the tyrosine phosphorylation of cellular proteins, in particular that of focal adhesion kinase (FAK) (18). Little is known about the mechanism of action of LOX-PP. Here, we have asked whether the tumor suppressor activity of LOX-PP attenuates the activation of the integrin signaling pathway in breast malignancy cells. We statement that LOX-PP attenuates FAK signaling and activation of its downstream target.